B
MEDIFAST INC — Earnings Quality Grade B
MED · Consumer Cyclical
Generally healthy
Revenue
$386M
2025
Net Income
-$19M
2025
Gross Margin
71.3%
Free Cash Flow
$1M
01
Screening Summary
11
Passed
3
Watch
0
Failed
—
M-Score
管理层信号
最近 SEC 8-K 文件中未发现 CEO、CFO、董事会或审计负责人变动信号。
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
✓
A3Revenue vs CFFO
Revenue -36.0%, CFFO -72.0%. Cash follows revenue
02
Expense Quality
✓
B1Inventory vs COGS
Inventory -52.3% vs COGS -29.9%. Normal
✓
B2CapEx vs Revenue
CapEx growth -24.7% vs revenue -36.0%. Normal
!
B3SG&A Ratio
SG&A/Gross Profit = 105.2%, exceeds 70%
✓
B4Gross Margin
Gross margin 71.3%, change -2.5pp. Stable
03
Cash Flow Quality
!
C1CFFO vs Net Income
CFFO/NI = -0.37. Below 1.0
✓
C2Free Cash Flow
FCF $0.0B, FCF/NI = -0.07
✓
C3Accruals Ratio
Accruals ratio = -10.3%. Low accruals
✓
C4Cash vs Debt
Cash $0.2B covers debt $0.0B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
!
D2Leverage
Debt/EBITDA = 368.8x (>4x). Financial stress
✓
D3Soft Asset Growth
Other assets -19.0% vs revenue -36.0%. Normal
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
✓
E1Serial Acquirer FCF
FCF after acquisitions positive
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
10.15
Safe Zone0 Distress1.102.605.0+ Safe
0.6401
Liquidity
0.6383
Cumulative profit
-0.0573
Operating efficiency
4.0552
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25